232 related articles for article (PubMed ID: 19204418)
1. The potential of a placebo/nocebo effect in pharmacogenetics.
Haga SB; Warner LR; O'Daniel J
Public Health Genomics; 2009; 12(3):158-62. PubMed ID: 19204418
[TBL] [Abstract][Full Text] [Related]
2. Nocebo phenomena in medicine: their relevance in everyday clinical practice.
Häuser W; Hansen E; Enck P
Dtsch Arztebl Int; 2012 Jun; 109(26):459-65. PubMed ID: 22833756
[TBL] [Abstract][Full Text] [Related]
3. Can insights from placebo and nocebo mechanisms studies improve the randomized controlled trial?
Vase L
Scand J Pain; 2020 Jul; 20(3):451-467. PubMed ID: 32609651
[TBL] [Abstract][Full Text] [Related]
4. The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.
Chavarria V; Vian J; Pereira C; Data-Franco J; Fernandes BS; Berk M; Dodd S
Clin Ther; 2017 Mar; 39(3):477-486. PubMed ID: 28237673
[TBL] [Abstract][Full Text] [Related]
5. Placebo and nocebo responses in drug trials of epilepsy.
Zaccara G; Giovannelli F; Schmidt D
Epilepsy Behav; 2015 Feb; 43():128-34. PubMed ID: 25703333
[TBL] [Abstract][Full Text] [Related]
6. Induction of nocebo and placebo effects on itch and pain by verbal suggestions.
van Laarhoven AIM; Vogelaar ML; Wilder-Smith OH; van Riel PLCM; van de Kerkhof PCM; Kraaimaat FW; Evers AWM
Pain; 2011 Jul; 152(7):1486-1494. PubMed ID: 21353388
[TBL] [Abstract][Full Text] [Related]
7. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
[TBL] [Abstract][Full Text] [Related]
8. The nocebo effect and its relevance for clinical practice.
Colloca L; Miller FG
Psychosom Med; 2011 Sep; 73(7):598-603. PubMed ID: 21862825
[TBL] [Abstract][Full Text] [Related]
9. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
Hafner S; Haubensak S; Paul T; Zolk O
Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
[No Abstract] [Full Text] [Related]
10. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.
Gervasini G; Benítez J; Carrillo JA
Eur J Clin Pharmacol; 2010 Aug; 66(8):755-74. PubMed ID: 20582584
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics: from discovery to patient care.
Shin J; Kayser SR; Langaee TY
Am J Health Syst Pharm; 2009 Apr; 66(7):625-37. PubMed ID: 19299369
[TBL] [Abstract][Full Text] [Related]
12. Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.
Solhaug V; Molden E
Scand J Pain; 2017 Oct; 17():193-200. PubMed ID: 29054049
[TBL] [Abstract][Full Text] [Related]
13. Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects.
Petrie KJ; Rief W
Annu Rev Psychol; 2019 Jan; 70():599-625. PubMed ID: 30110575
[TBL] [Abstract][Full Text] [Related]
14. [Placebo Nocebo Ethics in Communicating with Patients How Anaesthesiologists Should Handle the Psychosomatic Dimension of Briefing].
Friedrich DR; Reichardt JO; Rittner HL
Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Sep; 53(9):592-604. PubMed ID: 30176687
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of contextual factors as triggers of placebo and nocebo effects in musculoskeletal pain.
Rossettini G; Carlino E; Testa M
BMC Musculoskelet Disord; 2018 Jan; 19(1):27. PubMed ID: 29357856
[TBL] [Abstract][Full Text] [Related]
16. Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results.
Haga SB; Kawamoto K; Agans R; Ginsburg GS
Genet Med; 2011 Oct; 13(10):887-90. PubMed ID: 21673581
[TBL] [Abstract][Full Text] [Related]
17. [Placebo and nocebo : How can they be used or avoided?].
Hansen E; Zech N; Meissner K
Internist (Berl); 2017 Oct; 58(10):1102-1110. PubMed ID: 28702702
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacogenetic aspects of current pharmacotherapy].
Slanar O; Zima T
Cas Lek Cesk; 2010; 149(10):472-5. PubMed ID: 21121137
[TBL] [Abstract][Full Text] [Related]
19. Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions.
Haga SB; O'Daniel JM; Tindall GM; Lipkus IR; Agans R
Genet Med; 2011 Aug; 13(8):723-8. PubMed ID: 21633294
[TBL] [Abstract][Full Text] [Related]
20. Patients' and physicians' perspectives on pharmacogenetic testing.
Rogausch A; Prause D; Schallenberg A; Brockmöller J; Himmel W
Pharmacogenomics; 2006 Jan; 7(1):49-59. PubMed ID: 16354124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
